Clinical research company Medpace Holdings (NASDAQ:MEDP) will be reporting earnings this Wednesday after the bell. Here’s ...
Medpace has a strong financial position with high profit margins and low debt, and it has grown at a fast rate in the last five years. The company expects headwinds in 2025 in that it foresees that ...
StockStory.org on MSN
Medpace’s (NASDAQ:MEDP) Q1 CY2026 sales beat estimates but stock drops 19.8%
Clinical research company Medpace Holdings (NASDAQ:MEDP) reported Q1 CY2026 results , with sales up 26.5% year on year to ...
For this year, Medpace expects that its revenues will increase by 17.1%, which is an excellent growth rate. From 2019 to Q2 2025, Medpace's outstanding common shares declined by 22.16%, creating value ...
Hosted on MSN
Medpace (NASDAQ:MEDP) reports bullish Q4 CY2025
Clinical research company Medpace Holdings (NASDAQ:MEDP) reported Q4 CY2025 results , with sales up 32% year on year to $708.5 million. The company expects the full year’s revenue to be around $2.81 ...
Total revenue was up 9.3% on a year-over-year basis. New business awards totaled $500 million in the quarter, down 18.8% year-over-year. The company ended the period with a backlog of approximately $2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results